Benita A. Bamgbade

Benita A. Bamgbade

Auto-generated profile, based on publicly available information

Benita A. Bamgbade

Department of Pharmacy and Health Systems Sciences, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2022 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
WWWeijia Wang
Weijia Wang
DLDarleen Lessard
Darleen Lessard
CKCatarina I. Kiefe
Catarina I. Kiefe
RGRobert J. Goldberg
Robert J. Goldberg
DPDavid Parish
David Parish
JSJane S. Saczynski
Jane S. Saczynski

1 September 2020 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Open access
BBBenita A. Bamgbade
Benita A. Bamgbade
SSSaket R. Sanghai
Saket R. Sanghai
DMDavid D. McManus
David D. McManus
DLDarleen Lessard
Darleen Lessard
MWMolly Waring
Molly Waring
JSJane S. Saczynski
Jane S. Saczynski
Depression, anxiety, and cognitive impairments occur in up to 40 % of adults with AF and are associated with poorer health-related quality of life (HRQoL) and higher symptom burden. However, it is unknown how often these impairments co-occur, or multimorbidity, and how multimorbidity effects HRQoL and symptom burden. Patients with AF age ≥65 years with a CHA2DS2VASC risk score ≥ 2 and eligible for oral anticoagulation therapy were recruited from five clinics in a prospective cohort study. Participants completed validated measures of depression (PHQ9) and anxiety (GAD7), cognitive impairment (MoCA), and HRQOL and AF symptom burden (AFEQT). Multinomial logistic regression was used. Participants (N = 1244, 49 % female) were on average 76 ± 7 years; 86 % were non-Hispanic white. Approximately 35 % of participants had 1 impairment, 17 % had 2 impairments and 8% had 3 impairments; 39 % had none of the 3 impairments examined. Compared to participants with no impairments, patients with 1, 2 and 3 impairments had higher odds of poor HRQoL (adjusted OR [AOR] = 1.77, 95 % CI 1.21, 2.60; AOR = 6.64, 95 % CI 4.43, 9.96; and AOR = 7.50, 95 % CI 4.40, 12.77, respectively) and those with 2 and 3 impairments had higher odds of high symptom burden (AOR = 3.69 95 % CI 2.22, 6.13; and AOR = 5.41 95 % CI 2.85, 10.26). Psychosocial/cognitive multimorbidity is common among older adults with AF and is associated with poor HRQoL and high symptom burden. Clinicians might consider incorporating psychosocial and cognitive screens into routine care as this may identify a high-risk population.

23 June 2022 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
AKAnkur Karnik
Ankur Karnik
JSJane S. Saczynski
Jane S. Saczynski
JCJoseph J. Chung
Joseph J. Chung
JGJerry H. Gurwitz
Jerry H. Gurwitz
BBBenita A. Bamgbade
Benita A. Bamgbade
RHRobert H. Helm
Robert H. Helm

1 July 2018 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
SNSabina O. Nduaguba
Sabina O. Nduaguba
KFKentya H. Ford
Kentya H. Ford
BBBenita A. Bamgbade
Benita A. Bamgbade
OUOgechi Ubanyionwu
Ogechi Ubanyionwu

7 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
BBBenita A. Bamgbade
Benita A. Bamgbade
DMDavid D. McManus
David D. McManus
RHRobert Helm
Robert Helm
JMJordy Mehawej
Jordy Mehawej
JGJerry H. Gurwitz
Jerry H. Gurwitz
JSJane S. Saczynski
Jane S. Saczynski
Background: Little research has evaluated patient bleeding risk perceptions in comparison with calculated bleeding risk among oral anticoagulant users with atrial fibrillation. Our objective was to investigate underestimation of bleeding risk and to describe the characteristics and patient‐reported outcomes associated with underestimation of bleeding risk.Methods and Results: In the SAGE‐AF (Systematic Assessment of Geriatric Elements in Atrial Fibrillation) study, a prospective cohort study of patients ≥65 years with atrial fibrillation, a CHA2DS2‐VASc risk score ≥2 and who were on oral anticoagulant therapy, we compared patients’ self‐reported bleeding risk with their predicted bleeding risk from their HAS‐BLED score. Among the 754 participants (mean age 74.8 years, 48.3% women), 68.0% underestimated their bleeding risk. Participants who were Asian or Pacific Islander, Black, Native American or Alaskan Native, Mixed Race or Hispanic (non‐White) (adjusted OR [AOR], 0.45; 95% CI, 0.24–0.82) and women (AOR, 0.62; 95% CI, 0.40–0.95) had significantly lower odds of underestimating their bleeding risk than respective comparison groups. Participants with a history of bleeding (AOR, 3.07; 95% CI, 1.73–5.44) and prior hypertension (AOR, 4.33; 95% CI, 2.43–7.72), stroke (AOR, 5.18; 95% CI, 1.87–14.40), or renal disease (AOR, 5.05; 95% CI, 2.98–8.57) had significantly higher odds of underestimating their bleeding risk.Conclusions: We found that more than two‐thirds of patients with atrial fibrillation on oral anticoagulant therapy underestimated their bleeding risk and that participants with a history of bleeding and several comorbid conditions were more likely to underestimate their bleeding risk whereas non‐Whites and women were less likely to underestimate their bleeding risk. Clinicians should ensure that patients prescribed oral anticoagulant therapy have a thorough understanding of bleeding risk.

14 May 2024 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
DADeepti S. Athreya
Deepti S. Athreya
JSJane S. Saczynski
Jane S. Saczynski
JGJerry H. Gurwitz
Jerry H. Gurwitz
KMKevin M. Monahan
Kevin M. Monahan
BBBenita A. Bamgbade
Benita A. Bamgbade
RHRobert H. Helm
Robert H. Helm